The following is a summary of “Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis,” published in the January 2025 issue of Psychiatry by Fountoulakis et al.
Esketamine targets the glutamate neurotransmitter pathway, offering a novel mechanism for treatment-resistant depression. The treatment is available through a Risk Evaluation and Mitigation ...
Opens in a new tab or window The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral ...
Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback